The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
The entry deadline is Friday May 14
It is hoped that the multi-armed Octopus trial will rapidly speed up development of new treatments
Decision brings the innovative treatment to early-stage lung cancer patients, helping to address unmet need in this setting
Lucinda Sandon-Allum of Langland and winner in the 2020 Aspiring Communications Manager of the Year shares her competition highlights.
Collaboration will aim to improve understanding of prostate cancer and identify novel antibodies for the disease
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
The drug is the only biologic treatment approved in Europe that is specifically designed to work in systemic lupus erythematosus and lupus nephritis
MSF has applauded the move, but the IFPMA said the decision is “disappointing”
Funds will be used to advance company’s integrated physiological and digital biomarker platform
Checkpoint inhibitor specifically approved for patients with high PD-L1 expression
Managed access agreement treatment eligibility criteria extended following review
New facility will fast-track vaccines for COVID-19 variants to “future-proof the country”
The 2021 Clinical Researcher of the Year – The Americas competitions entry deadline has been extended to the 18th of June.
Scan enables doctors to diagnose coronary heart disease in 20 minutes, according to NHS England